Oncología Traslacional
ONCTRAS
![Foto de Oncología Traslacional](/img/uploaded/8edbe5178cdb32cce4e7d9c57e11add8.jpg)
![Foto de University of Antwerp](/img/noimage_org.png)
University of Antwerp
Amberes, BélgicaPublicaciones en colaboración con investigadores/as de University of Antwerp (5)
2023
-
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
European Journal of Cancer, Vol. 189
-
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Gynecologic Oncology, Vol. 170, pp. 300-308
2022
-
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43
2020
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
2019
-
Niraparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402